Compare Honeywell International Inc (HON) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Medpace Holdings Inc — how do they compare? Honeywell International Inc trades at $207.77 (market cap $65.48B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Honeywell International Inc is far larger — about 3.9× Medpace Holdings Inc's market cap, and Honeywell International Inc pays a 1.36% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Medpace Holdings Inc for 14 Days on average.
| HON | MEDP | |
|---|---|---|
Market Cap | $65.48B | $16.82B |
Volume | 2,047,782 | 223,093 |
Sector | Industrials | Health |
52-Week High | $248.79 | $630.19 |
52-Week Low | $188.14 | $393.42 |
Typical Hold Time | 91 Days | 14 Days |
Enterprise Value | $90.27B | $16.44B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.73, down 0.18% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 21.58% net margin and 47.43% ROE, trading at attractive valuations (P/E 7.94, EV/EBITDA 6.72). Recent Q2 2026 earnings beat expectations, and the company secured a $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with 67% buy ratings and $259.25 price target, representing 25% upside potential.
HON presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term caution. The company's post-spin focus on automation and recent contract wins provide growth catalysts, while rising debt levels and cyclical industrial exposure pose moderate risks. Wall Street optimism contrasts with current bearish technical positioning, creating potential for convergence if fundamentals drive price action.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
